Summary.-Seventy patients with Hodgkin's disease have been treated with a combination of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP).
THE MOPP (mustine, vincristine, procarbazine and prednisone) combination for the treatment of advanced Hodgkin's disease, introduced by De Vita, Serpick and Carbone in 1970, is the standard by which combination chemotherapy is judged in this disease. Vinblastine was substituted for vincristine to give MVPP (Nicholson et al., 1971; McElwain et al., 1973) . This combination gives the same remission rate and overall survival as MOPP, and has the advantage over MOPP of producing less neurotoxicity and epilation. However, MVPP retains a major side-effect also present in MOPP: the nausea and vomiting induced by nitrogen mustard. This is frequently so severe that patients need admission to hospital and heavy sedation. Also, nitrogen mustard must be given in a fast-running saline drip to prevent damage to veins. This results in the immobilization of the patient and is time-consuming for medical and nursing staff.
Since increasing numbers of patients with Hodgkin's disease are being treated with combination chemotherapy both as primary treatment and as an adjunct to radiotherapy, we felt that there was a need for a combination which could simply and safely be given to outpatients without the need for supplying a drip and without making them vomit. We therefore decided to replace the nitrogen mustard in the MVPP combination with oral chlorambucil, 6 mg/M2 daily for 14 days, not exceeding a dose of 10 mg/day. Chlorambucil in this dosage causes few if any ill effects, and in particular does not produce epilation or haemorrhagic cystitis, as is the case with i.v. cyclophosphamide, which has also been used as an alternative to nitrogen mustard. Our other reasons for choosing chlorambucil are summarized below:
(i) Chlorambucil as a single agent produces complete remission rates (16%) in Hodgkin's disease equivalent to those obtained with nitrogen mustard alone (13%) (Carter and Goldsmith, 1976 cumulative data). (ii) In combination with vinblastine, chlorambucil has produced a 60% complete remission rate in advanced Hodgkin's disease (Lacher and Durant, 1965 ).
(iii) Experimental studies (Harrap et al., 1975) (Ezdinli and Stutzman, 1965 Histology.-Histological classification was by the criteria of Lukes and Butler (1966) .
A total of 39 (560%) had nodular sclerosis (NS), 24 (34%0) had mixed cellularity (MC), 4 (6%) had lymphocyte predominance (LP) and 3 (4Oo) had lymphocyte depletion (LD). The 4 patients with LP were males; 21 (54%) of the patients with NS were males and 18 (460%) were females; 21 (88%) of the patients with MC were males and 3 (12%) were females; one patient with LD was male and 2 were females. Of the 47 male patients, 4 (S8%) had LP, 21 (45 0) had NS and 1 (2%) had LD. Of the 23 females, none had LP, 3 (13%) had MC, 18 (785o) had NS and 2 (9%0) had LD.
Previous treatment.-Thirty-six patients had received no previous treatment (NPT). These were either Stage III or IV patients in whom chemotherapy was the primary treatment, or patients with earlier-stage disease in whom chemotherapy was given electively to achieve complete remission prior to radiotherapy. Twenty-two patients had relapsed following radiotherapy (PRT), and 12 patients had relapsed following previous chemotherapy plus or minus previous radiotherapy (CT±RT). Details of these patients are given in Table I. Stage of disease.-The Ann Arbor staging system was used (Carbone et al., 1971 staged (CS) and 46 patients were pathologically staged (PS) by laparotomy with splenectomy and lvmph node, liver and bone biopsv specimens (Gazet, 1973 compares well with the complete remission rate of 76-6% previously reported by us for MVPP (McElwain et al., 1973) . Table II shows remission rates for each stage, and Table III shows details of remission rates for the 3 treatment groups of patients. Percentages in parentheses in Table III are the complete remission rates for the previously reported MVPP-treated patients. As in the MVPP series, the highest remission rate (91%) was seen in the group who had previously received radiotherapy, and may reflect the fact that many of these patients had a relatively small volume of disease at the time of starting chemotherapy. In the group who had received previous chemotherapy ± radiotherapy, all the patients had received MVPP, so it is perhaps not surprising that only 7/12 patients achieved complete remission with a combination Paraesthesiae due to vinblastine developed in a patients, but was never disabling. Five patients became constipated, but this could easily be relieved with milk of magnesia and liquid paraffin. Six patients noted some hairfall but none was epilated to the point where it was socially noticeable. Nineteen patients reported some nausea while taking the tablets: this was probably due to the procarbazine, and could be ameliorated with phenothiazine antiemetics. Six patients vomited after the Day 1 injection of vinblastine, but not after the Day 8 injection, and this did not occur with every course of treatment. The majoritv of patients suffered no nausea or vomiting, and routine prophylactic antiemetics were not given. Two women developed amenorrhoea and 2 patients noticed exacerbation of acne while taking prednisolone. One woman developed a steroid myopathy which totally resolved after completion of treatment.
No patient refused treatment.
MIany patients received their Dav 8 injection of vinblastine from their own general practitioner, which meant that they had only had to attend hospital outpatients once a month.
Bone marrow toxicity has not been a problem, dose-reduction being necessary in only a few patients. In 15 patients on 22 occasions, it was decided to delay the start of a course of treatment because of a depression of leucocyte or platelet count (WtBC < 3,000/mm3, platelets < 80,000/ mm3) In 9 ofthese patients, delay was only necessary on one occasion, and of the remaining 6, 5 had had previous treatment which probably compromised their bone marrow. A delav of more than 2 weeks was only necessarv on 2 occasions. MC disease in partial remission, developed Pneumocystis carinii pneumonia after 6 courses of treatment. He failed to respond to treatment with both pentamidine and cotrimoxazole. This is the first time we have seen this complication in a patient with Hodgkin's disease, although it is becoming increasingly common in children receiving chemotherapy for acute leukaemia. At a speculative level, it may be significant that he was followed up in a clinic with large numbers of leukaemic children who could constitute a reservoir of infection. In the "Previously Irradiated" group, there has been one death after failure to respond. In the "Previous Chemotherapy ± Radiotherapy" group, one patient relapsed 3 months after cessation of treatment. She had previously received MVPP, so it is perhaps not surprising that her response to ChlVPP was short-lived.
DISCUSSION
ChlVPP is a non-toxic, easily tolerated regime, which gives remission rates equivalent to those of MOPP or MVPP. The speed of response is also the same as that for combinations containing nitrogen mustard. This surprised us, since chlorambucil alone produces responses more slowly than nitrogen mustard alone.
The combination is well suited to use in outpatients and has meant that no patient has required admission to hospital for chemotherapy. This is particularly important in the case of children; there were 9 patients below the age of 13 in this series, and all tolerated their treatment well.
There is a real need for a non-toxic combination for treating Hodgkin's disease, particularly in view of the increasing tendency to combine chemotherapy and radiotherapy in the management of many patients. It is important that these patients should not be asked to bear more unpleasant side-effects from this protracted treatment than is absolutely necessary. Although we cannot yet know what the effect of ChlVPP will be on the long-term survival of patients treated with chemotherapy alone, we feel that the combination is a safe and easy way of treating patients in whom chemotherapy is used as an adjuvant either before or after radiotherapy and would confidently recommend it for this purpose. We are confident from our experience to date that Ch1VPP provides a good alternative to MVPP and deserves further study in relapsed patients and previously untreated late-stage patients.
